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Abstract
 
Tumor necrosis factor (TNF) is a proinflammatory cytokine, which is centrally involved in
several inflammatory disorders. Administration of TNF leads to a potentially lethal systemic in-
flammatory response syndrome (SIRS). We observed that (a) mice lacking functional genes for
metallothionein 1 and 2 (MT-null) were protected compared with wild-type controls (
 
P
 
 
 
 
 
0.0078), and (b) mice overexpressing MT-1 (MT-TG) were more sensitized for the lethal ef-
fect of TNF than control mice (
 
P
 
 
 
 
 
 0.0003), indicating a mediating role for MT in TNF in-
duced SIRS. As MT is involved in the body zinc homeostasis, we tested whether zinc-depriva-
tion or -supplementation alters the response to TNF. Although zinc-depletion strongly
sensitized (
 
P
 
 
 
 
 
 0.036), and pretreatment with zinc sulfate (ZnSO
 
4
 
) conferred protection against
the deleterious effects of TNF (
 
P
 
 
 
  
 
0.0002), it was also found that the protection provided by
zinc is independent of MT. Our observation that hsp70 is strongly induced in jejunum after
ZnSO
 
4
 
 treatment, suggests a contribution of hsp70 in the protection against TNF. In addition,
ZnSO
 
4
 
 cotreatment allowed complete regression of inoculated tumors with TNF and inter-
feron 
 
 
 
, leading to a significantly better survival (
 
P
 
 
 
 
 
 0.0045).
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Introduction
 
During systemic bacterial infection animals achieve an in-
ternal homeostasis by balancing the activities of proinflam-
matory and antiinflammatory pathways. TNF is considered
to be a major early mediator in the systemic inflammatory
response syndrome (SIRS)
 
*
 
 observed during Gram-nega-
tive sepsis (1). Intravenous injection of TNF in wild-type
(wt) mice causes acute weight loss, metabolic derangement,
hypotension, and at very high doses, shock, bowel necrosis,
hepatitis, and death as a result of induction of SIRS (2).
The toxicity and lethality induced by TNF is largely de-
pendent on the presence and absence of endogenous sensi-
tizing or protective factors: e.g., we showed previously that
IL-12 or a glucocorticoid antagonist drastically sensitize for
the lethal effects of TNF (3, 4), while inversely, acute phase
proteins protect (5–7). Recently, we also demonstrated the
involvement of leptin in the endogenous protective mech-
anisms (8). In our attempts to elucidate the mechanisms by
which leptin confers this protection we observed that lep-
tin was a potent inducer of metallothionein (MT) both in
vitro and in vivo (9).
 
The latter are members of a family of heavy-metal-bind-
ing proteins that have been highly conserved during evolu-
tion and are ubiquitously found in the animal kingdom.
MTs have remarkable biochemical properties and are char-
acterized by their low molecular weight (6–7 kD), high
cysteine content, lack of aromatic amino acids, and the
presence of 7–12 metal atoms per molecule. Zinc coordina-
tion includes four protein ligands (metal mercaptides)
closely arranged in the linear sequence of the protein, lead-
ing to a unique structural motif known as zinc cluster of
metallothionein. In mammals, MTs predominantly bind
zinc, but it can easily be displaced by copper, cadmium, and
traces of other metals. Besides by metal displacement, zinc
is also released from MTs through oxidation of the multiple
cysteine residues. MTs have been postulated to function in
the Zn and Cu homeostasis, to participate in the inflamma-
tory stress response and to be involved in the detoxification
of heavy metals and scavenging of free radicals (10).
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*
 
Abbreviations used in this paper: 
 
ALT, alanine aminotransferase; SAP, se-
rum amyloid P; SIRS, systemic inflammatory response syndrome; wt,
wild-type. 
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Of the four mouse MT-genes, the MT-1 and MT-2
genes are expressed in almost all organs in any stage of de-
velopment. These genes are constitutively expressed in the
liver and are highly induced during inflammation, and by
metals and glucocorticoids (10). Injection of a variety of
cytokines like TNF, IL-1, IL-6, leptin, and IFN-
 
 
 
 induces
hepatic MT gene expression in vivo (9, 11, 12).
The functions of MT-1 and MT-2 have been examined
in mice by inactivating both genes and also by overexpress-
ing MT-1 gene. MT-null mice are phenotypically normal,
but are more sensitive to cadmium and oxidant toxicity,
and showed reduced zinc-uptake capabilities, indicating
that the zinc homeostasis in these animals is disturbed (13).
Similarly, MT-1 overexpression has no obvious influence
on the phenotype, except that they were found to be more
resistant to zinc depletion when fed on a zinc-free diet (14).
The aim of this study was to explore the role of MT in
TNF-induced lethal shock using wt, MT-null mice, and
MT-1 transgenic mice. A secondary objective was to inves-
tigate the role of zinc in TNF-induced inflammation and
the potential use of zinc in TNF-based antitumor therapy.
 
Materials and Methods
 
Animals.
 
Specific pathogen-free female 129S7/SvEvBrd-
Mt1
 
tm1Bri
 
 Mt2
 
tm1Bri
 
 (hereafter referred to as MT-null mice) and
their control strain 129S3/SvImJ were obtained from The Jack-
son Laboratory. C57BL/6J-TgN(Mt1)174Bri (hereafter referred
to as MT-TG mice) and control strain C57BL/6J were also ob-
tained from The Jackson Laboratory. Mice were used at the age
of 9–10 wk. C57BL/6J mice, obtained from Iffa-Credo were
used in the antitumor and zinc supplementation experiments at
the age of 8–12 wk. All animals were housed in a temperature-
controlled environment with 12 h light/dark cycles and received
water and food ad libitum. The genotypes of the different strains
were regularly monitored by DNA analysis of tail-tip samples as
described by The Jackson Laboratory. Rectal body temperatures
were measured using an electronic thermometer (model 2001;
Comark Electronics). All experiments were performed according
to the European Guidelines on Animal Care and Use.
 
Reagents. Salmonella abortus equii
 
 LPS, ZnSO
 
4
 
 and D-(
 
 
 
)-
galactosamine (GalN) were purchased from Sigma-Aldrich. Re-
combinant murine TNF (mTNF) and recombinant murine IFN-
 
 
 
were produced in and purified from 
 
Escherichia coli
 
 in our labora-
tory. TNF had a specific activity of 1.0 
 
 
 
 10
 
9
 
 IU/mg and contained
 
 
 
0.02 ng endotoxin/mg protein, as assessed by a chromogenic
Limulus amebocyte lysate assay (Coatest; Chromogenix). IFN-
 
 
 
had a specific activity of 1.10
 
8
 
 IU/mg. TNF and IFN-
 
 
 
 were di-
luted in pyrogen-free PBS before injection. Intravenous injec-
tions had a volume of 0.2 ml and intraperitoneal injections were
in 0.5 ml. Antibodies for detection of serum amyloid P (SAP)
were purchased from Calbiochem. An anti–rabbit antibody, alka-
line phosphatase–coupled and alkaline phosphatase-coupled strepta-
vidin were from Sigma-Aldrich.
 
Measurement of IL-6, NO
 
x
 
, SAP, Alpha-1-Acid Glycoprotein,
Alanine Aminotransferase, and Apoptosis.
 
Blood was collected via
cardiac puncture, allowed to clot at 37
 
 
 
C, and subsequently cen-
trifuged to obtain serum. IL-6 was determined as described previ-
ously using the 7TD1 cell line in a hexosaminidase colorimetric
assay (15). As an estimate of NO concentration in serum, the sta-
ble NO metabolites nitrate and nitrite were measured together
 
(NO
 
x
 
) as described (16). SAP was measured by a sandwich
ELISA, also as described previously (17). Alpha-1-acid glycopro-
tein (AGP) was measured by ELISA using a rat anti–mouse AGP
monoclonal antibody (raised by C. Libert) and a rabbit polyclonal
antibody directed against mouse AGP (18). Serum alanine ami-
notransferase (ALT) was measured using a colorimetric test from
Sigma-Aldrich. Evaluation of apoptosis in hepatocytes was done
as follows: livers were perfused with 50 mM phosphate/120 mM
NaCl/10 mM EDTA pH 7.4 buffer, excised, and transferred to
ice-cold buffer (10 ml/g liver). The livers were homogenized us-
ing a douncer and DNA was prepared from 500 
 
 
 
l of liver ho-
mogenate. The proteins were extracted with phenol/chloro-
form/isoamyl alcohol (50/49/1) and with chloroform/isoamyl
alcohol (50/50). DNA was precipitated overnight with ammo-
nium acetate and ethanol at –20
 
 
 
C. DNA was dissolved in Tris/
EDTA and RNA was removed by RNase treatment. Plates were
then coated with an anti-histone (H2B) antibody and the cytoso-
lic fraction of the homogenized liver was used as an antigen
source. After incubation, a biotinylated secondary antibody, spe-
cific for the nucleosome subparticles of histones H2A, H2B, and
DNA (19), was added, followed by detection using an alkaline
phosphatase-conjugated streptavidine (Sanvertech) and substrate
(Sigma-Aldrich). Samples from untreated mice gave no signal in
the ELISA. The activity was expressed as U/ml, one unit being
the activity giving half maximal OD (405 nm).
 
Experimental Procedures.
 
ZnSO
 
4
 
 was dissolved in distilled wa-
ter at a concentration of 5 or 25 mM. Mice were treated with
ZnSO
 
4
 
 or distilled water for 7 d. The B16BL6 melanoma subline,
selected from a spontaneous melanoma B16F10 line by I. Hart
and syngeneic with C57BL/6 mice, was a generous gift from Dr.
M. Mareel, Ghent University, Ghent, Belgium (by courtesy of
Dr. I. Fidler, University of Texas, M.D. Anderson Cancer Cen-
ter, Houston, TX). Cells were expanded in vitro in DMEM con-
taining 10% FCS, L-glutamine, sodium pyruvate, nonessential
amino acids, MEM vitamins, penicillin, and streptomycin. At day
0 (the day of inoculation), cells were detached from the culture
flask by trypsin/EDTA treatment and washed three times with
serum-free medium and three times with pyrogen-free PBS.
500,000 tumor cells were inoculated by subcutaneous injection
in 0.1 ml in the right thigh of mice that were shaved the day be-
fore. The tumor size index (TSI) was obtained with the following
formula: largest diameter of the tumor 
 
 
 
 perpendicular diameter 
 
 
 
0.4. Treatment of tumor-bearing mice started at day 10 after in-
oculation. mTNF (10 
 
 
 
g/mouse) and IFN-
 
 
 
 (5,000 IU/mouse)
were injected simultaneously and paralesionally in a volume of
0.1 ml. Control groups received no treatment.
In the experiments assessing the effect of TNF toxicity on dif-
ferent strains, mice were challenged at 9 a.m. with different doses
(ranging from 5 to 25 
 
 
 
g) of mTNF intravenously. Survival was
monitored up to 96 h. Mice that survived were still alive several
weeks after the TNF treatment.
 
Statistical Analysis.
 
Survival curves (Kaplan-Meier plots) were
compared using a Log Rank-chi
 
2
 
 test, final outcomes using a chi
 
2
 
test and means with SD using a Student-
 
t
 
 test. 
 
*
 
 means 0.01 
 
  
 
P 
 
 
 
0.05, 
 
**
 
 0.001 
 
  
 
P
 
 
 
  
 
0.01, 
 
***
 
 
 
P 
 
  
 
0.001.
 
Tissue Sections and Staining.
 
The jejunum was dissected and
cut longitudinally and fixed in 10% formalin in PBS and embed-
ded paraffin. 5-
 
 
 
m sections were cut longitudinally and stained
with hematoxylin and eosin.
 
Hsp-70 Immunoblot.
 
Jejunum tissue was quickly removed af-
ter killing, immediately homogenized in 1 ml phosphate-buffered
saline (PBS) and centrifuged to remove undissolved material. To-
tal protein content was quantitated using the Bradford method. 
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3 
 
 
 
g of each sample was separated on a 7.5% SDS-PAGE and
transferred to nitrocellulose. The membranes were blocked with
1% gelatine blocking solution (PBS, 0.1% Tween20, 1% ge-
latine). Next, blots were exposed to a mouse anti-hsp70 biotin-
conjugated monoclonal antibody (StressGen Biotechnologies)
and peroxidase-conjugated streptavidin (Jackson Immunoresearch
Laboratories), respectively. After washing, blots were incubated
with SuperSignal West Pico Chemiluminescent Substrate (Pierce
Chemical Co.) and exposed to a standard autoradiographic film.
Efficiency of protein transfer on the membrane was checked by
staining with Ponceau S.
 
Results
 
Altered Sensitivity to TNF-induced Toxicity in MT-null and
MT-TG Mice.
 
To investigate the role of MT in TNF-
induced lethal shock, both MT-null mice and their appro-
priate controls (wt) were challenged with 10 
 
 
 
g mTNF/
mouse intravenously. All mice showed apparent signs of
distress such as apathy, fur ruffling, conjunctivitis, and diar-
rhea. These symptoms were more prominent in the control
group. The dose of 10 
 
 
 
g mTNF caused lethality in 100%
of the wt mice within 48 h after injection, whereas in the
MT-null group 47% survived (
 
**
 
P 
 
  
 
0.0078) (Fig. 1 A).
Administration of a lower dose mTNF (5 
 
 
 
g) was lethal in
47% of wt mice and 3% of the MT-null mice (
 
**
 
P 
 
 
 
0.0026; data not shown). Therefore, we conclude that tar-
geted disruption of the MT-1 and MT-2 gene significantly
increases the survival from TNF-induced shock.
To determine whether overexpression of MT influences
sensitivity to TNF induced lethal shock, MT-1 transgenic
mice and controls were treated with 7.5 
 
 
 
g mTNF. Symp-
toms of distress were present in both groups but were more
pronounced in MT-TG mice. Moreover, we observed a
survival rate of 78% in the control group whereas only 25%
of the MT-TG animals survived (
 
***
 
P 
 
 
 
 0.0003; Fig. 1 B).
These data were reproduced several times and are in line
with the former observation of decreased sensitivity of
MT-null mice.
 
The change of a number of metabolic parameters after
challenge with TNF was studied in wt and MT-knockout
mice. To investigate TNF-induced gene-expression, IL-6
and iNOS-produced NO
 
x
 
 were measured, respectively, 2
and 12 h after challenge with 7.5 
 
 
 
g mTNF and acute
phase proteins were measured 24 h after 1 
 
 
 
g mTNF. As is
clear from Table I
 
, 
 
IL-6, NOx, and acute phase proteins
were equally well induced in both groups of mice.
Recently, Kimura et al. described that MT-deficient
mice were more sensitive for LPS in GalN-sensitized mice
(20). We could confirm these data as, compared with con-
trols, MT-knockouts all died from a sublethal dose of 0.1
 
 
 
g LPS in combination with 20 mg GalN (see Table I).
However, MT-knockout mice were equally sensitive as
controls in a TNF/GalN model, as judged by final lethality,
drop in body temperature, appearance of liver ALT in the
serum, and liver apoptosis (Table I).
 
Influence of Zinc Supplementation or Deprivation on TNF-
induced Lethality.
 
As MT has been shown to play a prom-
inent role in the inflammation-mediated tissue Zn redis-
tribution (21), we examined whether alteration of zinc
metabolism could influence the sensitivity to the toxic ef-
fects of TNF. In a first experiment we tested whether zinc
supplementation could influence the response to TNF-
induced toxicity. Therefore, wt mice were pretreated for 1
wk with 5 or 25 mM ZnSO
 
4
 
 in the drinking water and
were challenged with 25 
 
 
 
g mTNF. Control mice, which
Figure 1. Sensitivity of MT-null and MT-TG mice to mTNF-induced
lethality. (A) Mice (wt, MT-null) were challenged with 10  g mTNF in-
travenously. The percentage survival was plotted as a function of time
(hours after challenge); n   18 (wt) and 18 (MT-null).  , wt;  , MT-
null. **P   0.0078 (wt versus MT-null). The result is a cumulative sum
of two independent experiments. (B) Mice (wt, MT-TG) were chal-
lenged with 7.5  g mTNF intravenously. The percentage survival was
plotted as a function of time (hours after challenge); n   28 (wt) and 20
(MT-TG).  , wt;  , MT-TG. ***P   0.0003 (wt versus MT-TG). The
result is a cumulative sum of three independent experiments.
 
Table I.
 
Changes of Metabolic Parameters upon Injection of
Wild-Type and MT-knockout Mice with TNF, TNF/GalN,
or LPS/GalN
 
Challenge
 
a
 
Parameter
 
b
 
wt MT-KO
 
P
 
 value
TNF IL-6 (ng/ml) 110 
 
  
 
15 88 
 
  
 
21 0.060 (N.S.)
NO
 
x
 
 (
 
 
 
M) 604 
 
  
 
44 538 
 
  
 
83 0.116 (N.S.)
SAP ( M) 206   50 195   25 0.672 (N.S.)
 -1-AGP 1,990   470 1,960   640 0.940 (N.S.)
TNF/GalN Lethality 5/5 5/5 1.000 (N.S.)
Body temp ( C) 29.7   1.6 32.1   1.7 0.051 (N.S.)
ALT (IU/liter) 7,259   7,203 5,779   3,487 0.690 (N.S.)
APO (U/ml) 244   56 272   45 0.465 (N.S.)
LPS/GalN Lethality 4/7 5/5 0.045 (*)
N.S., statistically not significant.
aTNF was injected intravenously at 7.5  g/mouse (IL-6 and NOx) or 1
 g/mouse (SAP and  -1-AGP); 0.5  g TNF was injected intraperito-
neally together with 20 mg GalN; 0.1  g LPS was injected intraperito-
neally together with 20 mg GalN.
bMeasured in serum, 2 h after challenge (IL-6), 12 h after challenge
(NOx) or 24 h after challenge (SAP,  -1-AGP); body temperatures
(Body temp), ALT, and apoptosis measured 6 h after challenge and le-
thality 24 h after challenge (no further deaths occurred).1620 Metallothionein in TNF-induced Shock
had received normal distilled water during 1 wk, all died
within 24 h after TNF administration. 5 mM ZnSO4 con-
ferred no protection, but 25 mM ZnSO4 lead to 100% pro-
tection (***P     0.0001; Fig. 2). Measurement of body
temperature and serum IL-6 concentrations, respectively, 6
and 8 h after TNF injection, confirmed that the inflamma-
tory response syndrome was attenuated by ZnSO4 pretreat-
ment (data not shown). Furthermore, 6 h after TNF-chal-
lenge, the jejunum of control mice displayed significant loss
of goblet cells, inflammatory cell infiltration, erosion, and
necrosis of the epithelium (Fig. 3 A). No tissue injury
could be demonstrated in the jejunum of the 25 mM
ZnSO4 treated group (Fig. 3 B). We conclude that pre-
treatment with ZnSO4 completely desensitizes wt mice to
TNF toxicity.
It is well known from literature that ZnSO4 treatment in
vivo results in hsp70 induction. To study the correlation
between zinc-induced protection and hsp70 induction,
mice were treated with water, 5 mM, or 25 mM ZnSO4
and after 1 wk, hsp70 induction in the jejunum was studied
by Western blot analysis. Preliminary data had shown that
hsp70 was strongly induced in the jejunum. It was found
(Fig. 4) that although there was detectable induction of
hsp70 after 5 mM ZnS04 treatment, a clearly more pro-
nounced induction was obtained after treatment with 25
mM ZnSO4.
Because zinc distribution is disturbed in MT-null mice
we also tested whether zinc supplementation or zinc depri-
vation could influence the protection against TNF induced
toxicity in these mutant mice. It was described before that
25 mM ZnS04 in the drinking water is not toxic to MT-
null mice (22). In a first experiment, we observed that, in
analogy with wt mice, MT-null mice could be perfectly
protected by adding 25 mM ZnS04 in the drinking water
(***P   0.0002; Fig. 5 A). In a second experiment wt mice
(129S3/SvImJ) as well as MT-null mice were kept on a
zinc deficient diet for 3 wk or on a normal control diet.
Next, mice were challenged with 250  g/kg mTNF intra-
Figure 2. Protective effect of
ZnSO4 on TNF-induced lethal-
ity. Mice were treated with H2O
(n   18), 5 mM ZnSO4 (n   6),
or 25 mM ZnSO4 (n   18) for a
period of 7 d, and were then
challenged intravenously with 25
 g mTNF. The percentage sur-
vival was plotted as a function of
time (hours after challenge).  ,
H2O;   , 5 mM;  , 25 mM
ZnSO4. ***P   0.0001.
Figure 3. Protective effect of ZnSO4 on TNF-induced bowel necrosis. Mice were treated with H20 (A) or 25 mM ZnSO4 (B) for a period of 7 d, and
were then challenged intravenously with 25  g TNF. 6 h after challenge, mice were killed and the bowels fixed in 10% formalin. Tissue sections were
made and stained with eosin/hematoxylin.1621 Waelput et al.
venously. In both the wt mice and the MT-null mice sur-
vival was higher in the normal fed group as opposed to the
zinc-deprived mice (*P   0.048 and *P   0.036 respec-
tively; Fig. 5 B). These data illustrate that loss of MT-1 and
MT-2 leads to protection to TNF, also in the absence of
zinc and that zinc-deprivation leads to sensitization in both
wt and MT-null mice. Administration of a dose of 500  g/
kg of mTNF to MT-null mice leads to a survival rate of
57% in the normal fed group, whereas no animals survived
in the zinc-deprived group (***P   0.0001), confirming
that zinc deprivation increases the susceptibility of MT-null
mice to TNF toxicity (Fig. 5 C). Though MT-null mice
are more sensitive to zinc deprivation (23), we observed
that zinc deprived MT-null mice are still more resistant
than zinc deprived wt mice (***P   0.0001; Fig. 5 B).
Influence of Zinc Supplementation on Antitumor Activities of
TNF. C57BL6/J mice were inoculated with B16BL6
syngeneic tumor cells on day 0. From day 3 until the end
of the experiment, mice received water with or without
addition of 25 mM ZnSO4. On day 10, mice were left un-
treated or were subjected to a 10-d treatment of daily in-
jection with 10  g mTNF in combination with 5,000 IU
mIFN- . Tumor size index (TSI) was measured daily. Af-
ter 10 d of treatment all surviving mice were killed. ZnSO4
did not inhibit the growth of the B16BL6 tumors; neither
did it affect the antitumor effect of TNF/IFN-  (Fig. 6).
Untreated tumor-bearing mice were all alive on day 20.
After 10 d of treatment with TNF/IFN- , the number of
mice that had succumbed was 8/12 in the control group
and 2/13 in the ZnSO4 group (**P   0.0045). From these
observations, we conclude that coadministration of ZnSO4
offers significantly better survival prognosis in TNF/IFN- 
antitumor therapy without impairing the antitumor effect.
Discussion
TNF, which was originally discovered based on its prop-
erty to destroy tumors in mice (24), is involved in the
pathogenesis of many inflammatory diseases. Administra-
tion of TNF leads to a widespread SIRS, which is estab-
lished by a complex network of cytokines, hormones, and
low-molecular weight mediators induced by TNF (25).
One of the cytokines that is induced by TNF is leptin, a
hormone secreted by adipocytes which modulates food in-
take and energy metabolism (26, 27). Recently, we showed
that leptin has protective properties against the toxicity ex-
erted by TNF (8). Using a Representational Difference
Analysis-strategy in PC12 cells stably expressing the leptin
receptor, we were able to identify a set of leptin-induced
genes (9). One of these genes encoded MT-2, which was
of particular interest since we were able to demonstrate
modulation of MT mRNA and protein levels by leptin
both in vitro (PC12 cells) and in vivo (in wt and ob/ob
mice). Moreover, several publications indicate that MT has
a protective role against oxidative damage (11, 28–31) and
that oxidative stress is implicated in the mechanism of
TNF-induced cell death (32). To address the question
whether MT could also protect against the toxic effects of
TNF, we studied the lethal response in MT-null and MT-
TG mice by challenging them with TNF intravenously. To
our surprise, survival was significantly higher in MT-null
mice than in wt control mice, whereas MT-TG mice ex-
hibited an increased sensitivity in comparison with the ap-
propriate control population. This observation claims a
crucial role for MT in mediating the harmful effects of
TNF to the host, which is in marked contrast with a po-
tentially protective effect of MT in SIRS (10). Indeed, it
Figure 4. Western blot analysis of hsp 70 protein expression in je-
junum tissue after pretreatment with ZnSO4. Animals were treated for 1
wk in the drinking water either with 0 mM, 5 mM, or 25 mM ZnSO4 as
indicated on top.
Figure 5. (A) Protective effect
of ZnSO4 on TNF-induced le-
thality in MT-null mice. Mice
were treated with H2O (n   7)
or 25 mM ZnSO4 (n   6) for a
period of 7 d, and were then
challenged intravenously with
12.5  g mTNF.  , H2O;  , 25
mM ZnSO4. ***P   0.0002. (B)
Sensitivity of normal fed MT-null,
normal fed wt mice, zinc-deprived
MT-null, and zinc-deprived wt
mice to mTNF-induced lethal-
ity. Mice were challenged with
250  g/kg mTNF intravenously.
The percentage survival was
plotted as a function of time (hours after challenge); n   23 (MT-null, normal diet), n   45 (wt, normal diet), n   32 (MT-null, zinc deficient diet), n  
43 (wt, zinc deficient diet);  , MT-null, normal diet;  , wt, normal diet;  , MT-null zinc deficient diet;  , wt, zinc deficient diet. The result is a
cumulative sum of three independent experiments. Survival curves were significantly different between a and b: *P   0.048, c and d: *P   0.036, a–c:
***P   0.0001, b–d: ***P   0.0001. (C) Sensitivity of normal fed MT-null and zinc deprived MT-null mice to mTNF-induced lethality. Mice were
challenged with 500  g/kg mTNF intravenously. The percentage survival was plotted as a function of time (hours after challenge);  , MT-null, normal
diet (n   19);  , MT-null, zinc deficient diet (n   20), P   0.0001.1622 Metallothionein in TNF-induced Shock
was recently shown that MT-deficient mice were more
sensitive in a model of LPS induced lethal shock in GalN-
sensitized mice (20). We found a similar sensitization in this
model but not in the TNF/GalN model, which may be re-
lated to the scavenging of reactive oxygen species, involved
in the induction of TNF by LPS (33). It was found by these
authors that antioxidantia such as allopurinol, or detoxify-
ing enzymes such as superoxide dismutase and catalase pro-
tected against LPS/GalN but not against TNF/GalN. The
loss of antioxidant MT activity in the TNF model is there-
fore clearly irrelevant.
As loss of MT leads to slightly increased NF- B activity
in cells (34) we studied the nuclear factor (NF)-kB and
p38 dependent gene-induction by TNF in wt as well as
MT knockout mice and found no difference whatsoever.
These data illustrate that the resistance of MT-deficient
mice to TNF is independent from NF-kB–mediated gene
expression. We also followed induction of acute phase
proteins and found no difference between control and
MT-null mice. This is in agreement with the data of Rofe
et al. who found no changes in fibrinogen increase after
LPS treatment (35).
To exclude that the effect we observed is merely a sec-
ondary effect of an altered zinc distribution in MT-null
mice, we repeated the TNF challenge experiments in zinc
limiting conditions. It has been shown before that MT-null
mice have higher serum zinc and lower hepatic zinc level
in comparison with the normal wt mice. Moreover, LPS
administration leads to hypozincemia and increased hepatic
zinc levels in wt mice within a few hours, while plasma
zinc and hepatic zinc concentrations remain unchanged in
MT-null mice (35). It was also demonstrated that zinc dep-
rivation leads to low plasma zinc concentrations and low
liver zinc concentrations in wt and MT-null mice, with
bottom levels that are the same in both genotypes (23).
Here, we show that zinc withdrawal clearly increased the
sensitivity of both MT-null and wt mice to TNF toxicity.
Moreover, we found that zinc deprived MT-null mice are
still more protected in comparison with the zinc-deprived
wt mice, which argues strongly for a zinc-independent role
for MT in mediating the toxic effects of TNF.
In this study we also provide evidence that the survival
rate after TNF challenge is significantly enhanced in
ZnSO4 pretreated animals. Previously, Klosterhalfen and
coworkers obtained similar data in a porcine model with
LPS, which is a potent inducer of TNF. They showed that
pretreatment with Zn2  led to lower plasma peak levels of
proinflammatory mediators like IL-1, IL-6, thromboxane-
B2, and TNF after LPS administration, as opposed to the
untreated group (36). Likewise, intraperitoneal administra-
tion of zinc chloride decreased liver damage and increased
survival of rats against LPS (37). Although these data
strongly suggest that protection provided by ZnSO4 against
LPS and TNF is based on the same mechanism, it is not
fully understood.
Several metal responsive genes may play a role in the zinc
mediated protection against TNF. One of the candidate
genes is the hsp70 gene, which is induced in vivo by heavy
metals (36). Overexpression of hsp70 protects against TNF-
induced damage in several cell types (38, 39). Furthermore,
rat hsp70-transgenic mice are protected in a model of isch-
emic heart failure, a disease in which TNF is a central
mediator (40, 41). Using Western blot analysis, we found
indeed induction of hsp70 in the jejunum after treatment of
the mice with ZnSO4. Metal ions are also potent inducers
of MT-1 and MT-2, a phenomenon linked to their role in
heavy metal detoxification (42). The decreased sensitivity of
MT-null mice and the increased sensitivity of MT-TG mice
to TNF, is at odds with a role for MT in the zinc-induced
protection against TNF toxicity. Moreover, MT-null mice
pretreated with ZnSO4 are more protected than untreated
MT-null mice, indicating that the protection provided by
ZnSO4 is established by an MT-independent mechanism.
Further studies will be necessary to reveal the mecha-
nisms by which ZnSO4 exerts its protective effects and to
determine the precise contribution of hsp70 induction.
The advantageous properties of ZnSO4 may not be limited
to the protection against TNF systemic response. ZnSO4
treatment may also provide protection in other pathologi-
cal conditions in which TNF plays a mediating, detrimental
role, such as rheumatoid arthritis, infectious disease, and in-
flammatory bowel disease (1). Furthermore, our survival
data suggest that ZnSO4-cotreatment could have beneficial
effects in cancer therapy. As systemic treatment with TNF
leads to major side effects like hypotension, liver toxicity,
and bowel necrosis, TNF therapy is currently limited to
isolated organ perfusion settings (e.g., of limbs). It can be
expected that if one succeeds in reducing the concomitant
side effects, wider regional and even systemic application of
TNF in cancer treatment may be reconsidered.
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Figure 6. Influence of ZnSO4 treatment on tumor growth and TNF/
IFN-  induced antitumor activity. Tumor cells were inoculated subcuta-
neous and tumors were allowed to grow for a period of 10 d. Mice were
either pretreated with H2O or with 25 mM ZnSO4 from day 3 after inoc-
ulation. 10 d after inoculation, mice were treated daily with TNF/IFN- 
or were not treated at all.  , H2O, untreated (n   8);  , ZnSO4, un-
treated (n   8);  , H2O, TNF/IFN- -treated (n   12);  , ZnSO4,
TNF/IFN- –treated (n   13).1623 Waelput et al.
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